Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent use of rifampicin and protease inhibitors. We investigated whether dose escalation of atazanavir/ritonavir could safely overcome the DDI with rifampicin.
This featured research paper was written in part by members of our Uganda chapter. For more information on this local chapter, visit this page.